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Summary Intracerebral (i.c.) and subcutaneous (s.c.) 9L tumours were treated simultaneously with various
doses of the nitrosoureas, BCNU or CCNU, and 2.5mmolkg-1 of misonidazole (MISO). After 24h, tumours
were removed, dissociated into single cell suspensions and the cells plated for colony formation. In both i.c.
and s.c. tumours, no cell kill was observed after exposure to MISO alone, and no additional cell kill was
observed when MISO was combined with either nitrosourea. If s.c. 9L tumours were clamped 30min after i.p.
injection of 2.5mmolkg-1 MISO, then 2h later the clamps were removed and the nitrosourea injected, an
increase in cell kill was observed. This increase in cell kill was statistically significant (P<0.01) for each dose
of BCNU administered, but not statistically significant (P>0.05) for the moderate dose of CCNU
administered. Clamping did not alter the colony forming efficiency of cells from untreated 9L s.c. tumours or
from those treated with each drug alone. These data demonstrate that hypoxic cells are required for
misonidazole to potentiate the cell-killing effects of the nitrosoureas and that s.c. 9L tumours contain no such
cells.
Recent data have suggested that protocols
combining the radiosensitizer, misonidazole
(MISO), with bifunctional alkylating agents and
several nitrosoureas may be useful for the treatment
of human malignancies (Clement et al., 1980; Law
et al., 1981; Martin et al., 1981; Mulcahy et al.,
1981; Rose et al., 1980; Siemann, 1981; Siemann &
Sutherland, 1982; Tannock, 1980; Twentyman,
1981). Several mechanisms have been proposed to
explain the interaction observed between MISO and
these chemotherapeutic agents (for reviews - see
McNally, 1982; Brown, 1982; Siemann, 1982).
These mechanisms include: (1) the additive effects
of killing hypoxic cells with MISO and oxic cells
with chemotherapeutic agents, (2) the alteration of
the chemotherapeutic agent pharmacokinetics by
MISO, (3) the effects of MISO on the recovery
from drug-induced potentially lethal damage
(PLD), and (4) the manifestations of the
"preincubation effect" observed in vitro.
In vitro "pre-incubation" or "co-incubation"
studies have clearly demonstrated a requirement for
metabolism of the sensitizer under hypoxic
conditions to observe chemopotentiation (Stratford
et al., 1980; Roizin-Towle & Hall, 1981; Mulcahy &
Dembs, 1983; Siemann et al., 1984). Direct evidence
for such a requirement in solid tumours is lacking.
Indirect evidence using tumours of different sizes
(and different hypoxic fractions) does suggest that
hypoxic cells may be required for the interaction
between MISO and various chemotherapeutic
agents (Martin et al., 1981; Spooner et al., 1982),
but other explanations may also be feasible
(Siemann, 1982). In an attempt to provide more
direct evidence for the role of hypoxic cells in
chemopotentiation, i.c. and unclamped or clamped
s.c. 9L tumours were treated with combinations of
MISO and either BCNU or CCNU. Intracerebral
9L tumours have been shown to contain no
hypoxic cells (Wheeler & Wallen, 1980; Wheeler et
al., 1984), and 30mg to -2000mg s.c. 9L tumours
are thought to contain no hypoxic cells (Wallen et
al., 1980; Wheeler et al., 1984). In addition, i.c. 9L
tumours have been shown to exhibit no recovery
from either BCNU- or CCNU-induced PLD
(Rosemblum et al., 1975b, 1976, 1977), so
mechanistically the requirement for hypoxic cells
can be separated from inhibition of recovery from
drug-induced PLD in this study.
Materials and methods
In situ tumour systems
The origin of the 9L cell line (Schmidek et al.,
1971; Wheeler et al., 1984), the methods for
maintaining the cells in culture (Wheeler et al.,
1984), the implantation procedures for i.c. (Barker
et al., 1973; Wheeler et al., 1979) and s.c. (Wallen
et al., 1980) tumours, and the in situ growth
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characteristics (Wheeler & Wallen, 1980) have been
described previously. Treatment was initiated either
12 days after implantation (i.c. tumours) or when
the tumours were 200-500mg (s.c. tumours).
Drug preparation
BCNU and CCNU were obtained from Dr R.
Engle at the Drug Research and Development
Branch, and MISO was obtained from Dr V.
Narayanan at the Drug Synthesis and Chemistry
Branch of the National Cancer Institute. BCNU
was dissolved in ethanol and diluted in sterile saline
to the final concentrations for injection. CCNU was
dissolved in ethanol and diluted to the final
concentrations for injection in a 0.3% solution of
hydroxypropyl-methylcellulose (HPMC) in saline.
MISO was dissolved in normal saline (25mgml-1).
BCNU and CCNU were held in ethanol until
immediately (<3min) before injection.
Unclamped experiments
Rats bearing i.c. or s.c. 9L/Ro tumours were
injected i.p. with BCNU (3,6, 9, 12, or 15mgkg')
or CCNU (4,8,12,16, or 20mgkg-1) either alone or
simultaneously with 2.5mmolkg- 1 (0.5mgkg-1) of
MISO. After 20-24h, the rats were killed by
cervical dislocation, the tumours removed and
assayed for colony formation as previously
described (Rosenblum et al., 1975a; Wallen et al.,
1980). Tumours from rats injected with saline,
MISO alone or HPMC were handled similarly and
assayed in each experiment. An amount of saline
equivalent to that injected in the combined
protocols was always given simultaneously with the
single agent treatments, so the volume of fluid/kg
body wt remained constant for each treatment.
Clamped experiments
Rats bearing s.c. tumours were anaesthetized with
sodium pentobarbital and then injected with either
saline or MISO. After 30min the tumours were
tightly clamped with a plastic, double-soft jaw,
handless vascular clamp (Stewart et al., 1983). Two
hours later the clamps were removed. the tumours
gently rubbed to help restore the circulation and
then the rats injected i.p. with either BCNU (3 or
6 mgkg-1) or CCNU (8 mgkg-1). Tumours were
removed 20-24h later and assayed as described
above. The following groups were included in each
clamped experiment: unclamped, saline +clamp,
MISO+clamp, saline +clamp +BCNU or CCNU,
and MISO+clamp+BCNU or CCNU. In some
experiments s.c. tumours were irradiated with a
Phillips X-ray machine (250kVp, 15mA,
HVL=0.5mm Cu, dose rate=3Gymin-1) and
assayed for colony formation as described above.
These radiation experiments included unclamped
tumours, tumours clamped for 2 h and tumours
clamped for 2h then unclamped before irradiation.
Results
No cell kill was observed after i.c. or clamped and
unclamped s.c. 9L tumors were treated with MISO
or HPMC (data not shown). No cell kill in clamped
tumors treated with 2.5mM is consistent with the
results of the in vitro 9L experiments (Siemann et
al., 1984). In both i.c. (Figure 1) and unclamped
s.c. (Figures 2 and 3) tumours, MISO combined
with either BCNU or CCNU produced no
additional cell kill. For comparison, the BCNU
dose response data (X's) of Rosenblum et al.
(1975b) is shown in Figure 1.
When s.c. 9L tumours were clamped 30min after
injection of 2.5mmolkg-1 of MISO, then 2h later
the clamps released and either 3 mgkg- 1 or
6mgkg-1 of BCNU injected, a significant
(P<0.01) increase in cell kill over that of the
appropriate controls was observed (Table I). An
increase in cell kill that was not statistically
(P>0.05) different from the appropriate controls
Table I Summary ofclamped 9L s.c. tumour experiments
Fraction survival
Treatment (±s.e.) no. oftumours P value
3mgkg 1 BCNU controlsa 0.77+0.04 8
MISO+clamp+3mgkg-1
BCNU 0.41+0.09 4 <0.01
6mgkg-BCNU controlsa 0.28+0.11 8
MISO+clamp+6mgkg-1
BCNU <5x10-4 4 <0.01
8mgkg-1 CCNU controls' 0.13 +0.04 10
MISO+clamp+8mgkg-1
CCNU 0.055+0.008 5 >0.05
aBCNU controls=BCNU alone, MISO+BCNU, clamp+BCNU.
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Figure 1 Dose response curve for cells from i.c. 9L tumours treated in situ with either BCNU alone (@, *)
or BCNU and MISO 2.5mmolkg-' (0, El) given simultaneously. Cell survival was assayed 20-24h after
treatment. Each symbol represents the results from an individual tumour; different symbols represent the
results from separate experiments. The BCNU alone data represented by the symbol X are taken from
Rosenblum et al., 1975b.
was also observed when 8 mgkg-1 of CCNU was
injected (Table I). Therefore, the magnitude of the
increase in cell kill appeared to be both dose-
dependent and drug-dependent. Cells in s.c.
tumours clamped for 2h and then released prior to
treatment with BCNU, CCNU or X-rays were
killed identically to those in similarly treated
unclamped tumours. The oxygen enhancement ratio
(o.e.r.) for the clamped tumours was 1.8+0.4, a
value consistent with the 1.5 previously reported for
s.c. 9L tumours rendered anoxic by nitrogen
asphyxiation (Wallen et al., 1980).
Discussion
The failure of MISO to either kill 9L cells or
potentiate the BCNU-induced cell kill in i.c. 9L
brain tumours (Figure 1) may be caused by several
factors. First, MISO might not kill hypoxic 9L cells
or potentiate the cell kill produced by BCNU even
if MISO were preincubated with hypoxic 9L cells.
Our in vitro experiments with exponentially growing
9L cells (Siemann et al., 1984) demonstrate that
MISO can kill hypoxic 9L cells and potentiate
BCNU-induced cell kill when preincubated under
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Figure 2 Dose response curve for cells from s.c. 9L tumours treated in situ with either BCNU alone (0) or
BCNU and MISO 2.5mmolkg-' (0) given simultaneously. Cell survival was assayed 20-24h after treatment.
Each symbol represents the results from an individual tumour.
hypoxic conditions in a manner similar to that
reported by others (Stratford et al., 1980; Roizin-
Towle & Hall, 1981; Mulcahy & Dembs, 1983).
Therefore, neither of these factors is probably
responsible for the failure of MISO to potentiate
BCNU-induced cell kill in i.c. 9L tumours. Second,
because the i.c. 9L tumours have a growth fraction
of -0.4 (Barker et al., 1973), they may contain
many cells whose environment and metabolic state
might be more like plateau phase cells rather than
exponentially growing cells. These plateau phase
cells might not show the MISO-BCNU
"preincubation effect." Again, the in vitro data
(Siemann et al., 1984) which show good chemo-
potentiation of BCNU by MISO in plateau 9L cells
indicate that this is probably not responsible for the
failure to observe a MISO-BCNU interaction in
situ.
Finally, it could be argued that effective
concentrations of MISO did not reach the 9L brain
tumours, thereby preventing any interaction from
being observed. To evaluate this, intracerebral
tumours were removed 30min after injecting MISO
and assayed for MISO concentration using an
HPLC technique. Intratumour levels of
280yugml-1, which should be sufficient to get a
MISO-BCNU interaction, were measured.
Several other possibilities could account for a
failure to detect chemopotentiation in the i.c. 9L
brain tumour studies. The choice of the nitrosourea
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Figure 3 Dose response curve for cells from s.c. 9L tumours treated in situ with CCNU alone (0) or CCNU
and MISO 2.5mmolkg- (El) given simultaneously. Cell survival was assayed 20-24h after treatment. Each
symbol represents the results from an individual tumour.
in the drug combination may not have been
optimal since in most tumour systems MISO has
been significantly more effective at enhancing the
efficacy of CCNU than of BCNU (e.g., Mulcahy,
1982; Siemann & Mulcahy, 1982). The absence of a
shoulder on the BCNU alone dose response curve
for the i.c. 9L tumours might prevent a MISO-
BCNU interaction from being observed because
MISO has been shown to be particularly effective
at removing the shoulder on the drug dose response
curve (Stratford et al., 1980; Roizin-Towle & Hall,
1981; Siemann et al., 1984). If the mechanism by
which MISO potentiates the cell killing effects of
BCNU is inhibition of recovery from BCNU-
induced PLD, MISO may not be able to potentiate
the effects of BCNU in i.c. 9L tumours because no
recovery from BCNU-induced PLD occurs
(Rosenblum et al., 1975b, 1976, 1977). Finally, if
metabolism of MISO by hypoxic cells is required to
obtain a MISO-BCNU interaction on i.c. 9L
tumours, no interaction would be expected because
i.c. 9L tumours contain no hypoxic cells (Wheeler
& Wallen, 1980; Wheeler et al., 1984).
To distinguish among these possibilities, similar
experiments were performed on s.c. 9L tumours.
The dose response curves for cells from s.c. 9L
tumours generated after treatment with either
BCNU or CCNU had a distinct shoulder (Figures
2 and 3), but no interaction with MISO was
observed with either drug. Therefore, failure to
observe a MISO-BCNU interaction in i.c. 9L
tumours was not due to the absence of a shoulder792 K.T. WHEELER et al.
on the BCNU dose response curve (Figure 1) or to
the use of BCNU instead of CCNU.
It has been argued that 30-2000mg s.c. 9L
tumours contain no hypoxic cells (Wallen et al.,
1980). However, unlike i.c. tumours, these s.c.
tumours can be clamped to produce a reversible
state of hypoxia within the tumours so that in situ
experiments identical to the in vitro
"preincubation" experiments can be performed.
The o.e.r. obtained by clamping these s.c. tumours
was 1.8 +0.4, a value consistent with the 1.5
measured when s.c. tumours were rendered anoxic
after nitrogen asphyxiation of tumour-bearing rats
(Wallen et al., 1980). Cell kill was identical to that
found in unclamped tumours if the tumours were
irradiated 5min after unclamping or treated with
either BCNU or CCNU less than 1 min after
unclamping. Therefore, no evidence existed to
suggest that clamping the tumours subsequently
altered either the tumour vasculature or the drug
pharmacokinetics. All drug alone and MISO-drug
combination controls were performed in each
clamped experiment. When the surviving fraction of
the drug alone controls from the clamped
experiments where the rats were anaesthetized were
combined (Table I), the data fit on the dose
response curves generated in unanaesthetized rats
(Figures 2 and 3). Therefore, the results of the
clamped experiments were not due to the
anaesthesia. In summary, all the evidence suggests
that clamping these s.c. 9L tumours does little
except temporarily disrupt the flow of blood to the
tumours, thereby creating a temporary hypoxia
with its attendant alterations in environment and
cell metabolism.
The results of these investigations have failed to
demonstrate chemopotentiation in i.c. or s.c. 9L
tumours in air-breathing rats. However,
chemopotentiation could be demonstrated in s.c. 9L
tumours made artificially hypoxic prior to
treatment with the chemotherapeutic agents. These
findings imply that hypoxic cells are required for
MISO to potentiate the cell killing effects of
various chemotherapeutic agents in situ. Finally, as
has been argued previously from radiation studies
(Wallen et al., 1980). the present data support the
hypothesis that s.c. 9L tumours contain no hypoxic
cells. Therefore, the intermediate radiation dose
response curve previously reported for s.c. 9L
tumours (Wallen et al., 1980) must be generated by
as yet undefined factors that could be ultimately
important for limiting the radiocurability of
tumours.
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